Gentian Diagnostics ASA — Earnings Release 2019

Aug 15, 2019

2nd quarter and first half 2019 report

2nd quarter and first half 2019 report

Moss 15.08.19

Gentian Diagnostics AS announces its results for the second quarter and first half of 2019. The highlights include:

• 16 % growth in sales revenue in 2Q19 compared to 2Q18

• Total sales revenues of MNOK 10.2 in 2Q19, up from MNOK 8.8 in 2Q18

• FDA 510(k) clearance for the BÜHLMANN fCAL® turbo and with this access to the US market

• In July, Beckman Coulter, one of the top 5 global diagnostics companies, and Gentian have prolongated the trusted partnership agreement by another 6 years

• In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG

Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.

For further information, please contact:

Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525